PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
Adopting the final Annual Report
PHI intends to convene a general meeting to adopt the annual report for the fiscal year 2023/2024 and to amend resolutions regarding election of board members and the number of board members.
PostNews
BioStock: PHI’s new CEO: “I am excited to lead us forward with new energy”
Anders Månsson was recently appointed CEO of Phase Holographic Imaging. With extensive leadership experience in the international life sciences sector, he aims to expand PHI’s global reach and position the company as a leader in non-invasive cell quality control technologies. BioStock spoke with him about his vision for the future.
PostNews: Press Release
Bulletin from the annual general meeting of Phase Holographic Imaging PHI AB (publ)
Phase Holographic Imaging PHI AB (publ) held its annual general meeting on 31 October 2024. The following resolutions were made.
PostNews: Press Release
PHI secures a loan from Altium SA
Phase Holographic Imaging PHI AB (“PHI”) announces that the Company has been provided a loan of SEK 7 million from the main shareholder Altium SA. PHI and Altium SA are also in dialogues regarding long-term financing of PHI.
PostNews: Press Release
PHI AB’s warrant exercise registered at the Swedish Companies Registration Office
Phase Holographic Imaging PHI AB (“PHI” or “Company”) today announces that the new shares from the exercise of warrants of series TO 4 have been registered at the Swedish Companies Registration Office.
PostNews: Press Release
PHI appoints Anders Månsson as new CEO
The board of Phase Holographic Imaging (PHI) has today appointed Anders Månsson as the new CEO of PHI as of November 1, 2024. The current CEO, Patrik Eschricht, will remain in his role until November 1, 2024, and ensure a smooth handover to Anders Månsson.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
BioStock: PHI “It’s the right moment to capitalize on regenerative medicine momentum.”
BioStock contacted CEO Patrik Eschricht for an update on the company’s progress and how PHI will capitalize on the current momentum.
BioStock: Shift to regenerative medicine increases growth prospects for PHI
BioStock talked to our CEO, Patrik Eschricht, for an operational overview and to learn about the current behind-the-scenes developments, as PHI has a growth trajectory that is on a notable upward trend, marked by its highest-ever sales performances in the last quarter.
BioStock: PHI “We aim to revolutionize the regenerative medicine market“
BioStock talked to PHI’s CEO, Patrik Eschricht, about the eventful past year and his vision for the company’s future within regenerative medicine.
BioStock: PHI’s CEO reflects on the Company’s momentum
BioStock reached out to PHI’s CEO, Patrik Eschricht, to delve into what latest developments have contributed to the heightened enthusiasm surrounding the company.
